

STUDIES ON SEMI-SYNTHETIC  
7 $\alpha$ -FORMAMIDOCEPHALOSPORINS

I. STRUCTURE-ACTIVITY  
RELATIONSHIPS IN SOME  
SEMI-SYNTHETIC 7 $\alpha$ -FORMAMIDO-  
CEPHALOSPORINS

Sir:

The isolation<sup>1)</sup> of 7 $\alpha$ -methoxycephalosporins from *Streptomyces* species in 1971 stimulated considerable interest<sup>2)</sup> in the synthesis of 7 $\alpha$ (6 $\alpha$ )-substituted cephalosporins and penicillins. However, other than the methoxy group, only few<sup>3,4)</sup> 7 $\alpha$ (6 $\alpha$ )-substituents lead to antibacterially active compounds. One notable exception is the 7 $\alpha$ (6 $\alpha$ )-formamido group<sup>5)</sup>, discovered through a chemical programme<sup>6)</sup> designed to identify  $\beta$ -lactamase stable antibiotics. Subsequently other workers have described the isolation and antibacterial properties of several naturally occurring 7 $\alpha$ -formamidocephalosporins from *Flavobacterium*, *Lysobacter* and *Xanthomonas* species<sup>7-12)</sup>, and 3 $\alpha$ -formamidonocardicin analogues from *Flexibacter aliginoliquefaciens*<sup>13,14)</sup>. We have previously reported<sup>15)</sup> the antibacterial activity of BRL 36650, a 6 $\alpha$ -formamidopenicillin with exceptional activity against *Pseudomonas* species and against members of the family Enterobacteriaceae, and some preliminary structure-activity relationships of other 6 $\alpha$ -formamidopenicillins have been published<sup>6,16)</sup>. This communication describes a comparison of activity of some 7 $\alpha$ -substituted cephalosporins with the corresponding 7 $\alpha$ -formamido analogue, and then outlines some structure-activity relationships in a series of these formamidocephalosporins.

The synthesis of the 3-(acetoxymethyl)cephems is most conveniently carried out by direct acylation of the 7 $\alpha$ -formamido nucleus<sup>5)</sup> (**1**) with the appropriate activated side chain acid. Alternatively they may be prepared by a similar acylation of the 7 $\alpha$ -(methylthio) nucleus (**2**) followed by amination (NH<sub>3</sub>, Hg(OAc)<sub>2</sub>, DMF, -40°C) and formylation, or through acylation of the 7 $\alpha$ -formamidocephaloglycin ester (**4**). 3-[(Heterocycl)thiomethyl]cephems are obtained by coupling the nucleus (*e.g.*, **3**) with a suitable phenylglycine derivative. Standard deprotection conditions (TFA or TFA/anisole) then afford the desired 7 $\alpha$ -formamidocephalosporins. A full account of the synthesis and chemistry of

these compounds is to be published elsewhere<sup>17)</sup>.

The antibacterial activity of the 7 $\alpha$ -formamidocephoperazone analogue (**8**) compared with other related 7 $\alpha$ -substituted cephalosporin derivatives is shown in Table 1. The four compounds (**5**~**8**) were active against members of the family Enterobacteriaceae and, with the exception of the 7 $\alpha$ -(hydroxymethyl) compound (**7**), showed some activity against Gram-positive bacteria. The advantage of the 7 $\alpha$ -substituted cephalosporins (**6**~**8**) over the unsubstituted derivative (**5**) is their greater stability to bacterial  $\beta$ -lactamases. This may be seen by comparison of their activity against *Escherichia coli* DCO and the corresponding plasmid-mediated  $\beta$ -lactamase producing strain, *E. coli* DCO RTEM. The 7 $\alpha$ -formamido substituent is particularly advantageous compared with 7 $\alpha$ -methoxy and 7 $\alpha$ -(hydroxymethyl) substituents as it confers greater intrinsic activity against Gram-negative bacteria, including *Pseudomonas aeruginosa*.

In an attempt to improve upon this activity, several other ureido and acylamino cephalosporins were prepared. The activity of some of these (**9**~**12**) is shown in Table 1. However, the 7 $\alpha$ -formamidocephoperazone analogue (**8**) remained the most potent of the cephalosporins tested, being at least 2~4-fold more active than the other ureido or acylamino derivatives.

Alternative approaches to improve the activity of **8** included substitution at C-3 and derivatisations of the phenyl ring. It will be seen from Table 1 that introduction of a 3-[(*N*-methyltetrazolyl)thiomethyl] group results in a 2-fold increase in activity against all the bacteria tested (see compound **13**). This level of activity is maintained by introduction of a 4-hydroxy substituent into the phenyl ring (compound **14**). However, further substitutions, giving the 3,4-dihydroxy derivative (**15**), results in a pronounced increase in activity against Gram-negative organisms, albeit at the expense of some activity against Gram-positive bacteria. Overall, compound **15** possessed very potent activity particularly against strains of *E. coli*, *Klebsiella pneumoniae* and *P. aeruginosa*.

These results show that although the naturally occurring 7 $\alpha$ -formamidocephalosporins have only poor antibacterial activity<sup>7,8,12)</sup> there are semisynthetic derivatives which display outstanding broad-spectrum activity, with demonstrable advantages *in vitro* over the newer cepha-

Table 1. The relative antibacterial activities<sup>a</sup> *in vitro* of some 7 $\alpha$ -formamido and 7 $\alpha$ -substituted cephalosporins.


Organism	5	6	7	8	9	10	11	12	13	14	15	CPZ	CAZ
<i>Escherichia coli</i> NCTC 10418	0.25	0.25	2.0	0.12	4.0	0.12	2.0	2.0	0.06	0.06	$\leq 0.03$	$\leq 0.06$	0.12
<i>E. coli</i> DCO	2.0	2.0	2.0	0.25	16	—	—	—	0.12	0.12	$\leq 0.03$	$\leq 0.06$	0.12
<i>E. coli</i> DCO RTEM <sup>b</sup>	32	2.0	4.0	0.25	16	0.12	1.0	1.0	0.12	0.12	$\leq 0.03$	1.0	0.25
<i>Enterobacter cloacae</i> N1	4.0	8.0	8.0	1.0	64	16	4.0	16	0.5	0.5	0.12	2.0	0.25
<i>Klebsiella pneumoniae</i> T767	2.0	4.0	0.5	0.12	32	2.0	1.0	4.0	0.12	0.25	$\leq 0.03$	0.25	0.25
<i>Proteus mirabilis</i> C977	2.0	2.0	2.0	0.5	32	8.0	2.0	4.0	0.5	0.5	0.12	1.0	0.12
<i>Serratia marcescens</i> US32	16	64	4.0	1.0	64	8.0	4.0	8.0	0.25	0.25	0.12	2.0	0.5
<i>Pseudomonas aeruginosa</i> NCTC 10662	8.0	64	>128	8.0	64	0.5	32	32	4.0	4.0	0.25	4.0	1.0
<i>P. aeruginosa</i> Dalgleish <sup>b</sup>	64	128	>128	4.0	32	0.5	32	32	4.0	4.0	0.25	32	0.5
<i>Staphylococcus aureus</i> Oxford	1.0	8.0	>128	8.0	8.0	16	8.0	8.0	4.0	8.0	16	2.0	8.0
<i>S. aureus</i> Russell <sup>b</sup>	16	8.0	>128	8.0	8.0	16	4.0	8.0	4.0	8.0	16	16	16
<i>Streptococcus pyogenes</i> CN10	0.12	1.0	128	1.0	0.25	8.0	0.5	—	0.12	0.25	0.5	0.12	0.12

<sup>a</sup> MICs ( $\mu\text{g/ml}$ ) determined by serial dilution in nutrient agar containing 5% defibrinated horse blood, inoculum 0.001 ml of an overnight broth culture.


<sup>b</sup> Plasmid-mediated  $\beta$ -lactamase-producing strain.

CPZ: Cefoperazone.


CAZ: Ceftazidime.




- 1  $R_1 = \text{NHCHO}$   $R_2 = \text{OAc}$   $R_3 = t\text{Bu}$   
 2  $R_1 = \text{SCH}_3$   $R_2 = \text{OAc}$   $R_3 = t\text{Bu}$   
 3  $R_1 = \text{NHCHO}$   $R_2 = \text{STet}$   $R_3 = \text{CHPh}_2$








4




- 5  $R = \text{H}$       7  $R = \text{CH}_2\text{OH}$   
 6  $R = \text{OCH}_3$     8  $R = \text{NHCHO}$



9 - 12



13 - 15

13  $\text{Ar} = \text{Ph}$ 14  $\text{Ar} =$  15  $\text{Ar} =$  

losporins, cefoperazone and ceftazidime. Further modifications to optimise activity in this series are under investigation and will be the subject of further publications.

#### Acknowledgement

The authors are indebted to Mrs. S. J. KNOTT for antibacterial susceptibility testing, and Miss J. FARLEY for technical assistance.

MICHAEL J. BASKER  
 CLIVE L. BRANCH  
 STEPHEN C. FINCH  
 ANGELA W. GUEST  
 PETER H. MILNER\*

MICHAEL J. PEARSON  
 ROGER J. PONSFORD  
 TERENCE C. SMALE

Beecham Pharmaceuticals,  
 Chemotherapeutic Research Centre,  
 Brockham Park, Betchworth,  
 Surrey, RH3 7AJ, U.K.

(Received July 24, 1986)

#### References

- 1) NAGARAJAN, R.; L. D. BOECK, M. GORMAN, R. L. HAMILL, C. E. HIGGINS, M. M. HOEHN, W. M. STARK & J. G. WHITNEY:  $\beta$ -Lactam

- antibiotics from *Streptomyces*. J. Am. Chem. Soc. 93: 2308~2310, 1971
- 2) GORDON, E. M. & R. B. SYKES: Cephamicin antibiotics. In Chemistry and Biology of  $\beta$ -Lactam Antibiotics. Vol. 1. Eds., R. B. MORIN & M. GORMAN, pp. 199~370, Academic Press, London, 1982
  - 3) DIXON, R. A.; K. D. HARDY, A. C. KAURA, P. H. MILNER & A. W. TAYLOR: The synthesis and antibacterial activities of novel  $7\alpha$  substituted cephalosporins. J. Antibiotics 37: 1732~1735, 1984
  - 4) DIXON, R. A.; R. A. EDMONDSON, K. D. HARDY & P. H. MILNER: The synthesis and antibacterial activity of some  $\beta$ -lactamase stable  $6\alpha$ -(hydroxymethyl)penicillins. J. Antibiotics 37: 1729~1731, 1984
  - 5) MILNER, P.H.; A. W. GUEST, F.P. HARRINGTON, R.J. PONSFORD, T.C. SMALE & A.V. STACHULSKI:  $6\alpha(7\alpha)$ -Formamido penicillins and cephalosporins. J. Chem. Soc. Chem. Commun. 1984: 1335~1336, 1984
  - 6) PONSFORD, R. J.; M. J. BASKER, G. BURTON, A. W. GUEST, F. P. HARRINGTON, P. H. MILNER, M. J. PEARSON, T. C. SMALE & A. V. STACHULSKI: Recent advances in the chemistry and biology of penicillins. In Recent Advances in the Chemistry of  $\beta$ -Lactam Antibiotics. Eds., A. G. BROWN & S. M. ROBERTS, pp. 32~51, The Chemical Society, London, 1985
  - 7) SINGH, P. D.; M. G. YOUNG, J. H. JOHNSON, C. M. CIMARUSTI & R. B. SYKES: Bacterial production of 7-formamidocephalosporins. Isolation and structure determination. J. Antibiotics 37: 773~780, 1984
  - 8) SHOJI, J.; T. KATO, R. SAKAZAKI, W. NAGATA, Y. TERUI, Y. NAKAGAWA, M. SHIRO, K. MATSUMOTO, T. HATTORI, T. YOSHIDA & E. KONDO: Chitinovorins A, B and C, novel  $\beta$ -lactam antibiotics of bacterial origin. J. Antibiotics 37: 1486~1490, 1984
  - 9) ONO, H.; Y. NOZAKI, N. KATAYAMA & H. OKAZAKI: Cephacins, new cephem antibiotics of bacterial origin. I. Discovery and taxonomy of the producing organisms and fermentation. J. Antibiotics 37: 1528~1535, 1984
  - 10) HARADA, S.; S. TSUBOTANI, H. ONO & H. OKAZAKI: Cephacins, new cephem antibiotics of bacterial origin. II. Isolation and characterization. J. Antibiotics 37: 1536~1545, 1984
  - 11) TSUBOTANI, S.; T. HIDA, F. KASAHARA, Y. WADA & S. HARADA: Cephacins, new cephem antibiotics of bacterial origin. III. Structural determination. J. Antibiotics 37: 1546~1554, 1984
  - 12) NOZAKI, Y.; K. OKONOJI, N. KATAYAMA, H. ONO, S. HARADA, M. KONDO & H. OKAZAKI: Cephacins, new cephem antibiotics of bacterial origin. IV. Antibacterial activities, stability to  $\beta$ -lactamases and mode of action. J. Antibiotics 37: 1555~1565, 1984
  - 13) KATAYAMA, N.; Y. NOZAKI, K. OKONOJI, H. ONO, S. HARADA & H. OKAZAKI: Formadins, new monocyclic  $\beta$ -lactam antibiotics of bacterial origin. I. Taxonomy, fermentation and biological activities. J. Antibiotics 38: 1117~1127, 1985
  - 14) HIDA, T.; S. TSUBOTANI, N. KATAYAMA, H. OKAZAKI & S. HARADA: Formadins, new monocyclic  $\beta$ -lactam antibiotics of bacterial origin. II. Isolation, characterization and structures. J. Antibiotics 38: 1128~1140, 1985
  - 15) BASKER, M. J.; R. A. EDMONDSON, S. J. KNOTT, R. J. PONSFORD, B. SLOCOMBE & S. J. WHITE: In vitro antibacterial properties of BRL 36650, a novel  $6\alpha$ -substituted penicillin. Antimicrob. Agents Chemother. 26: 734~740, 1984
  - 16) GUEST, A.W.; F.P. HARRINGTON, P.H. MILNER, R.J. PONSFORD, T.C. SMALE, A.V. STACHULSKI, M. J. BASKER & B. SLOCOMBE: Structure-activity relationships of some  $6\alpha$ -formamido penicillins. J. Antibiotics 39: 1498~1501, 1986
  - 17) GUEST, A. W.; C. L. BRANCH, S. C. FINCH, A. C. KAURA, P. H. MILNER, M. J. PEARSON, R. J. PONSFORD & T. C. SMALE: Preparation and properties of  $7\alpha$ -formamido cephalosporins. J. Chem. Soc. Perkin Trans. I, 1986, in press